Regeneron Presents Positive Interim Data from Phase 2 ProofofConcept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

TARRYTOWN N.Y. May 31 2016 PRNewswire &160;Regeneron Pharmaceuticals Inc. NASDAQ REGN today announced that positive preliminary results from an ongoing proofofconcept study of evinacumab REGN1500 in patients with Homozygous Familial Hypercholestrolemia...